Objective To evaluate the strategy using cyanoacrylate tissue adhesive (CTA) in amniotic membrane transplantaton(AMT) to manage corneoscleral melting in severe ocular burns. Methods Twelve eyes from eleven patients with chemical or thermal burns of grade Ⅳ were recruited for this study.After medical treatment failed to arrest corneal or sclera melting,CTA were applied directly on the ulcerating corneal or sclera surface to augmented AMT. Results In all cases,all sclera ulcerations (five of eleven) were prevented or healed,epithelialization of burned cornea (eight of eleven) was complete,corneal ulceration in the rest three eyes was successfully arrested. Conclusion Tissue adhesive aided amniotic membrane transplantation is a promising altermnative in managing severe corneoscleral melting in chemical or thermal burns to maintain the integrity of the ocular wall.

Objective To study the clinical results of phacoemulsification with foldable posterior chamber intraocular lens implantation(PC-IOL) in the management of angle-closure glaucoma with cataract.Methods Phacoemulsification with PC-IOL implantation was performed on 58 eyes(52 cases),after a mean postoperative follow-up of (16.50?6.20) months.Results The best corrected visual acuity was improved in 53 of 58 eyes.The intraocular pressure was reduced from a preoperative mean of (19.56?3.36)mmHg to a postoperative mean of (14.26?3.20)mmHg(P

A series of new monobactam sulfonates is continuously synthesized and evaluated for their antimicrobial efficacies against Gram-negative bacteria. Compound 33a (IMBZ18G) is highly effective in vitro and in vivo against clinically intractable multi-drug-resistant (MDR) Gram-negative strains, with a highly druglike nature. The checkerboard assay reveals its significant synergistic effect with β-lactamase inhibitor avibactam, and the MIC values against MDR enterobacteria were reduced up to 4-512 folds. X-ray co-crystal and chemoproteomic assays indicate that the anti-MDR bacteria effect of 33a results from the dual inhibition of the common PBP3 and some class A and C β-lactamases. Accordingly, preclinical studies of 33a alone and 33a‒avibactam combination as potential innovative candidates are actively going on, in the treatment of β-lactamase-producing MDR Gram-negative bacterial infections.